Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biological process
|
| gptkbp:associated_with |
immune evasion
immune checkpoint inhibitors NK cells |
| gptkbp:can_be |
gptkb:IgG_antibodies
flow cytometry small molecules therapeutic antibodies |
| gptkbp:enables |
immunosuppressive factors
|
| gptkbp:has_a_focus_on |
cancer immunotherapy
immunotherapy research |
| gptkbp:hasPrograms |
involves cell-mediated cytotoxicity
involves target cell destruction. |
| https://www.w3.org/2000/01/rdf-schema#label |
ADCC
|
| gptkbp:impact |
cytokines
genetic factors monoclonal antibodies adjuvants antigenic variation immune modulators |
| gptkbp:influenced |
tumor microenvironment
patient factors antibody affinity |
| gptkbp:involves |
antibodies
immune cells |
| gptkbp:is_a |
immune response
|
| gptkbp:is_a_key_component_of |
adaptive immunity
|
| gptkbp:is_a_source_of |
antibody-dependent cellular cytotoxicity
immune surveillance |
| gptkbp:is_a_subject_of |
scientific research
|
| gptkbp:is_a_time_for |
vaccine efficacy
antibody therapy |
| gptkbp:is_characterized_by |
target cell recognition
|
| gptkbp:is_essential_for |
therapeutic efficacy
viral infections |
| gptkbp:is_evaluated_by |
serological tests
|
| gptkbp:is_funded_by |
Fc receptors
|
| gptkbp:is_involved_in |
pathogen clearance
transplant rejection |
| gptkbp:is_linked_to |
clinical outcomes
therapeutic antibodies |
| gptkbp:is_part_of |
humoral immunity
|
| gptkbp:is_promoted_through |
combination therapies
|
| gptkbp:is_studied_in |
clinical trials
chronic infections |
| gptkbp:is_used_in |
cancer therapy
personalized medicine |
| gptkbp:leads |
tumor regression
|
| gptkbp:measures |
preclinical models
cytotoxicity assays |
| gptkbp:performedBy |
solid tumors
|
| gptkbp:related_to |
autoimmune diseases
infectious diseases HIV treatment |
| gptkbp:resultedIn |
cell lysis
|
| gptkbp:targets |
drug development
tumor cells |
| gptkbp:usedIn |
antigen expression
|
| gptkbp:was_a_factor_in |
tumor immunology
|